Table 1. Clinical response and survival in the GOG 111a and OV10b studies.

	No. of patients evaluable for clinical response		Overall response rate (%)		Complete response rate (%)		Median progression-free survival (months)		Overall median survival (months)
Treatment arm	GOG 111	OV10	GOG 111	OV10	GOG 111	OV10	GOG 111	OV10	GOG 111	OV10
Cisplatin+paclitaxel	100	162	73	58.6*	51*	40.7*	18*	15.5*	38*	35.6*
Cisplatin+cyclophosphamide	116	161	50	44.7	31	27.3	13	11.5	24	25.8

^aCisplatin 75 mg m⁻²+either paclitaxel 135 mg m⁻² over 24 h or cyclophosphamide 750 mg m⁻² every 3 weeks (McGuire et al, 1996).

^bCisplatin 75 mg m⁻²+either paclitaxel 175 mg m⁻² over 3 h or cyclophosphamide 750 mg m⁻² every 3 weeks (Piccart et al, 2000).

^*Statistically significant difference between treatments (P<0.05).